Galunisertib (LY2157299) monotherapy or with lomustine versus lomustine in recurrent glioblastoma
Glioblastoma
Enrolment: 158 · Results not recorded
Loading the evidence…
Drug
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Glioblastoma
Enrolment: 158 · Results not recorded
Acral Melanoma · Mucosal Melanoma
Enrolment: 14 · Results not recorded
Rectal Adenocarcinoma
Enrolment: 50 · Results not recorded
Nasopharyngeal Carcinoma
Enrolment: 206 · Results not recorded
Metastatic Colorectal Cancer · Gastric Cancer
Enrolment: 120 · Results not recorded
Desmoid Tumor
Enrolment: 24 · Results not recorded
Multiple Myeloma
Enrolment: 18 · Results not recorded
Pancreatic Cancer
Enrolment: 24 · Results not recorded
Metastatic Pancreatic Cancer
Enrolment: 37 · Results not recorded
Healthy Volunteers
Enrolment: 8 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Radiation-induced fibrosis of the left hind limb, delivered as two weekly 22 Gy fractions by linear accelerator; the topical experiment used a single 35 Gy dose
SKI2162 inhibited ALK5 with an IC50 of 0.094 micromolar and abolished TGF-beta1-induced Smad2 and Smad3 phosphorylation at 400 nanomolar. In mice it significantly reduced leg contracture from 6 to 16 weeks, lowered the 16-week late skin reaction score to 2.73 plus or minus 0.16 versus 3.14 plus or…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.